BKYI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BKYI is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock lacks supportive momentum, has no recent news catalyst, no bullish proprietary signal, and the latest quarter shows weakening growth. Based on the current data, I would not buy it now and would only consider it after a clear turnaround in price trend and fundamentals.
The technical picture is weak. MACD histogram is negative and still below zero, showing bearish momentum. RSI at 47.4 is neutral, so there is no oversold buying signal. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which confirms a downtrend structure. Price at 5.18 is just above the pivot of 5.155, but below the first resistance at 5.938 and with support at 4.372, so the stock is not showing a strong breakout setup. The short-term pattern projection is modestly positive, but not strong enough to override the broader bearish trend.
No news in the recent week. The only mild positive is that the stock is near the pivot level and the modeled short-term pattern suggests a possible small upside over the next week or month. There are no meaningful event-driven catalysts reported.
Revenue in 2025/Q3 fell 27.75% YoY, EPS declined to -1.46, and gross margin also slipped. Market sentiment is weak with no significant hedge fund activity and no insider buying trend. AI Stock Picker has no signal today, SwingMax has no recent signal, and there is no recent news to support a rerating. The stock is also trading under a bearish moving average structure.
In 2025/Q3, BIO-Key International reported revenue of 1,549,706, down 27.75% year over year, which signals contraction in the latest quarter. Net income improved year over year but remained negative at -964,849. EPS worsened to -1.46, down 62.66% YoY, and gross margin eased to 76.9%, down 1.80% YoY. Overall, the latest quarter shows weakening top-line growth and continued losses.
No analyst rating or price target change data was provided, so there is no recent Wall Street upgrade/downgrade trend to assess. Based on the available information, Wall Street pros would likely lean cautious to negative because the business is shrinking, profitability remains negative, and there is no visible catalyst or strong institutional support.
